Review
Oncology
Yujie Zhang, Zhichao Xing, Li Mi, Zhihui Li, Jingqiang Zhu, Tao Wei, Wenshuang Wu
Summary: Classical Hodgkin lymphoma, the most common type of HL, mainly affects people in certain age groups. A significant proportion of patients with refractory or relapsed cHL do not respond well to treatment. Exploring new predictive strategies and treatment measures may help improve the cure rate for these patients.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Michael P. Randall, Michael A. Spinner
Summary: The treatment landscape of relapsed/refractory classic Hodgkin lymphoma (cHL) has significantly evolved over the past decade and has led to improved cure rates and overall survival. This review discusses the management of first relapse, maintenance therapy after transplant, relapse after transplant, and treatment of older adults and frail patients. Additionally, emerging immunotherapies in clinical trials are highlighted.
Article
Hematology
Eleonora Calabretta, Anna Guidetti, Francesca Ricci, Martina Di Trani, Chiara Monfrini, Massimo Magagnoli, Stefania Bramanti, Davide Maspero, Lucia Morello, Michele Merli, Alice Di Rocco, Alex Graudenzi, Enrico Derenzini, Marco Antoniotti, Davide Rossi, Paolo Corradini, Armando Santoro, Carmelo Carlo-Stella
Summary: Checkpoint inhibitors (CPIs) are commonly used in relapsed/refractory classical Hodgkin lymphoma, but long-term responses are uncommon and about one-third of patients remain refractory. This study analyzed the response to chemotherapy after CPI failure and characterized the clonal evolution in a small sample of patients. The results showed that most patients achieved complete remission and a small percentage achieved partial remission after chemotherapy rechallenge. Importantly, salvage chemotherapy followed by stem cell transplantation was an effective strategy for rescued CPI failure patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Hematology
Liudmila V. Fedorova, Kirill V. Lepik, Natalia B. Mikhailova, Elena V. Kondakova, Yuri R. Zalyalov, Vadim V. Baykov, Elena V. Babenko, Andrey V. Kozlov, Ivan S. Moiseev, Boris V. Afanasyev
Summary: Immune checkpoint inhibitors have shown high therapeutic efficacy in relapsed or refractory classical Hodgkin lymphoma, with the potential for achieving durable remission. Retreatment with nivolumab has demonstrated high overall response rate and complete remission rate, with all patients alive at the final analysis. However, some patients may experience grade 3-4 adverse events during nivolumab retreatment.
ANNALS OF HEMATOLOGY
(2021)
Article
Health Care Sciences & Services
Jeremy A. Meier, Barbara Savoldo, Natalie S. Grover
Summary: Treatment for Hodgkin lymphoma has advanced significantly, but a portion of patients still experience relapse or disease progression. Immunotherapies, particularly CAR T cells, have shown exceptional promise in treating relapsed/refractory HL.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Hematology
Michael A. Spinner, R. A. Sica, John S. Tamaresis, Ying Lu, Cheryl Chang, Robert Lowsky, Matthew J. Frank, Laura J. Johnston, David B. Miklos, Lori S. Muff Ly, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Judith A. Shizuru, Wen -Kai Weng, Michael S. Binkley, Richard T. Hoppe, Ranjana H. Advani, Sally Arai
Summary: The treatment landscape of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has significantly changed over the past decade with the use of brentuximab vedotin (BV) and PD-1 inhibitors. A study comparing outcomes from 2011 to 2020 with those from 2001 to 2010 showed improved overall survival (OS) and increased postprogression survival in the modern era, attributed to the use of BV and PD-1 inhibitors. Factors associated with inferior progression-free survival (PFS) included age ≥45 years, primary refractory disease, and lack of complete remission pre-AHCT, while receipt of a PD-1 inhibitor-based regimen pre-AHCT was associated with superior PFS.
Article
Hematology
Pier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A. Johnson, Jose S. R. de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhit Ozcan, Naohiro Sekiguchi, Ying Zhu, Monika Raut, Todd L. Saretsky, Akash Nahar, John Kuruvilla
Summary: The study demonstrated significant improvements in health-related quality of life measures with pembrolizumab compared to brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma.
Article
Hematology
Tycel Phillips, Henry Chan, Constantine S. Tam, Alessandra Tedeschi, Patrick Johnston, Sung Yong Oh, Stephen Opat, Hyeon-Seok Eom, Heather Allewelt, Jennifer C. Stern, Ziwen Tan, William Novotny, Jane Huang, Judith Trotman
Summary: The study demonstrates favorable outcomes for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma treated with the selective Bruton's tyrosine kinase inhibitor zanubrutinib. The results support zanubrutinib as a potentially meaningful addition to available therapies for these patients.
Article
Oncology
Artem Gusak, Liudmila Fedorova, Kirill Lepik, Nikita Volkov, Marina Popova, Ivan Moiseev, Natalia Mikhailova, Vadim Baykov, Alexander Kulagin
Summary: Classic Hodgkin lymphoma involves rare malignant cells alongside abundant reactive populations in the tumor microenvironment. The microenvironment is crucial in tumor resistance and progression, yet its role during anti-PD-1 treatment remains unclear. This study aimed to identify predictive markers and assess reactive cell populations in patients treated with nivolumab for relapsed or refractory Hodgkin lymphoma. Results showed that a low number of macrophages in primary samples was associated with inferior progression-free survival during nivolumab treatment, while a low number of M2 was associated with higher PFS. In sequential samples, an increase in PD-1 and LAG-3 and a depletion of CD68 and CD163-positive cells were observed.
Article
Oncology
Neha Pathak, Raja Pramanik, Sameer Bakhshi, Akash Kumar, Mehar C. Sharma, Shamim A. Shamim, Sudhir Kumar, Sanjay Thulkar, Atul Sharma
Summary: This study analyzed the use of nivolumab in patients with r/rHL in India. The results showed that nivolumab demonstrated comparable efficacy and safety in a real-world setting, even with compromised dosing and schedule of administration.
JOURNAL OF IMMUNOTHERAPY
(2022)
Article
Immunology
Xianggui Yuan, Xian Li, Yurong Huang, Xueli Jin, Hui Liu, Aiqi Zhao, Weiping Zhang, Wenbin Qian, Yun Liang
Summary: This study evaluated the efficacy and safety of zanubrutinib plus salvage chemotherapy in R/R DLBCL patients and found that it showed high efficacy and manageable tolerability. Additionally, CAR-T cell therapy may be a priority strategy for poor responders to BTKi-based treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Tingting Qiu, Luan Hu, Yongtian Zhang, Ying Wang, Sha Ma, Depeng Li, Zhenyu Li, Kailin Xu
Summary: The study aimed to determine the clinical characteristics of cytopenia in patients with relapsed and refractory B-cell non-Hodgkin lymphoma (B-NHL) treated with CAR-T therapy. A total of 63 patients were retrospectively analyzed, and neutropenia, anemia, and thrombocytopenia occurred in 76.19%, 25.39%, and 23.80% cases, respectively. Baseline absolute neutrophil count (ANC) and hemoglobin concentration were identified as independent risk factors for severe cytopenia. Additionally, 35% of patients did not recover from cytopenia at day +28 after infusion, and baseline ANC and hemoglobin levels were found to affect hemocyte recovery.
Review
Oncology
Samer A. Al-Hadidi, Hun Ju Lee
Summary: Checkpoint inhibitors nivolumab and pembrolizumab are key treatment options for relapsed or refractory classic Hodgkin lymphoma, especially for patients unable to undergo stem-cell transplantation. These drugs may improve overall survival and have manageable side effects.
JCO ONCOLOGY PRACTICE
(2021)
Review
Oncology
Robert Stuver, Alison J. Moskowitz
Summary: T-cell lymphomas are a rare and diverse group of lymphomas derived from post-thymic T lymphocytes. Patients with relapsed or refractory disease have poor outcomes, with overall survival usually less than one year. Although historically non-overlapping combination chemotherapy has been used, recent advances in understanding the pathogenesis of these diseases have led to the development of novel and biologically rational therapies. This review evaluates the therapeutic advances for relapsed and refractory T-cell lymphomas, focusing on approved agents and promising investigational regimens within the last five years, and provides a framework for disease management.
Review
Medicine, General & Internal
Esther Hazane Leroyer, Caroline Ziegler, Charline Moulin, Arnaud Campidelli, Caroline Jacquet, Marie Therese Rubio, Pierre Feugier, Simona Pagliuca
Summary: This article discusses the application of immunotherapy in the treatment of relapsed/refractory HL, focusing on the role of anti-CD30 antibodies and checkpoint inhibitors, as well as the place of allogeneic stem cell transplantation in the era of novel therapies.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Cell & Tissue Engineering
Maja Stanojevic, Ashley Geiger, Brita Ostermeier, Danielle Sohai, Christopher Lazarski, Haili Lang, Mariah Jensen-Wachspress, Kathleen Webber, Peter Burbelo, Jeffrey Cohen, Michael D. Keller, Catherine M. Bollard, Conrad Russell Y. Cruz
Summary: The study found enhanced T-cell responses to coronavirus disease 2019 after vaccination.
Review
Hematology
Keri Toner, Catherine M. Bollard
Summary: Epstein-Barr virus (EBV) is a common human tumor virus associated with lymphoproliferative diseases. The presence of EBV provides a unique target for therapies targeting EBV.
Letter
Biophysics
Conrad Russell Y. Cruz, Na Bo, Giorgos Bakoyannis, Kaylor E. Wright, Elizabeth A. Chorvinsky, Allison Powell, Catherine M. Bollard, David Jacobsohn, Kenneth R. Cooke, Christine Duncan, Robert M. Krance, Paul A. Carpenter, Courtney M. Rowan, Sophie Paczesny
BONE MARROW TRANSPLANTATION
(2022)
Article
Cell & Tissue Engineering
Alexey Bersenev, Michael P. Gustafson, Patrick J. Hanley
Summary: The next generation of personalized medicine, such as CAR-T cell and gene therapy products, requires apheresis collection from patients or donors for manufacture and subsequent shipment to clinical sites. This new manufacturing paradigm involves multiple entities including apheresis centers, cell processing labs, sponsor manufacturing facilities, and clinical sites.
Editorial Material
Cell & Tissue Engineering
Patrick J. Hanley, Alexey Bersenev, Michael P. Gustafson
Article
Immunology
Susan R. Conway, Christopher A. Lazarski, Naomi E. Field, Mariah Jensen-Wachspress, Haili Lang, Vaishnavi Kankate, Jessica Durkee-Shock, Hannah Kinoshita, William Suslovic, Kathleen Webber, Karen Smith, Jeffrey I. Cohen, Peter D. Burbelo, Anqing Zhang, Stephen J. Teach, Trisha Ibeh, Meghan Delaney, Roberta L. DeBiasi, Michael D. Keller, Catherine M. Bollard
Summary: This study compared antigen-specific T cell (CST) responses between children and adults following SARS-CoV-2 infection and found differences in immune responses to the virus. Children showed weaker responses compared to adults, but those with MIS-C had stronger responses.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Blachy J. Davila Saldana, Tami John, Challice Bonifant, David Buchbinder, Sharat Chandra, Shanmuganathan Chandrakasan, Weni Chang, Leon Chen, Hannah L. Elfassy, Ashley Geerlinks, Roger H. Giller, Rakesh Goyal, David Hagin, Shahidul Islam, Kanwaldeep Mallhi, Holly K. Miller, William Owen, Martha Pacheco, Niraj C. Patel, Christiane Querfeld, Troy Quigg, Nameeta Richard, Deborah Schiff, Evan Shereck, Elizabeth Stenger, Michael B. Jordan, Helen E. Heslop, Catherine M. Bollard, Jeffrey Cohen
Summary: Chronic active Epstein-Barr virus (EBV) disease (CAEBV) is a common condition in Asia, characterized by high levels of EBV in T and/or natural killer cells, lymphoproliferation, organ failure, hemophagocytic lymphohistiocytosis, and/or lymphoma. Allogeneic hematopoietic stem cell transplantation (HSCT) is considered the only curative therapy for CAEBV, but its efficacy and the best treatment modality prior to HSCT are unclear.
Article
Cell & Tissue Engineering
Michael P. Gustafson, John A. Ligon, Alexey Bersenev, Chase D. McCann, Nirali N. Shah, Patrick J. Hanley
Summary: The field of cell and gene therapy in oncology has seen rapid progress since the approval of the first therapies in 2017. Multiple new products have been approved for additional indications, and efforts have been made to target different cancers, improve delivery logistics, and reduce costs. This review provides an overview of the current state of cell and gene therapy-based approaches for cancer treatment, discussing various effector cell types, genetic modifications, and promising approaches for improving therapeutic efficacy and persistence.
Article
Hematology
Jeremy Rubinstein, Keri Toner, Thomas Gross, Birte Wistinghausen
Summary: This review focuses on the epidemiology, role of EBV, clinical presentation, current treatment strategies, adoptive immunotherapy, and future research in pediatric patients with PTLD driven by EBV-positive CD20+ B-cell proliferations.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
(2023)
Article
Hematology
Christopher J. Forlenza, Jaclyn Rosenzweig, Audrey Mauguen, Ilia Buhtoiarov, Branko Cuglievan, Hema Dave, Rebecca J. Deyell, Jamie E. Flerlage, Anna K. Franklin, Jennifer Krajewski, Kasey J. Leger, Lianna J. Marks, Robin E. Norris, Martha Pacheco, Faye Willen, Adam Paul Yan, Paul D. Harker-Murray, Lisa Giulino-Roth
Summary: Through a retrospective analysis of 67 pediatric patients, it was found that brentuximab vedotin in combination with vedotin had good tolerability and a safety profile similar to that of adult patients in the treatment of relapsed/refractory Hodgkin lymphoma. With a median follow-up of 37 months, the 3-year progression-free survival was 85%. These data suggest a potential role for the use of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in children with relapsed/refractory Hodgkin lymphoma.
Article
Hematology
Jeremy D. Rubinstein, Sonata Jodele, Daria Heyenbruch, Jamie Wilhelm, Shawn Thomas, Carolyn Lutzko, Xiang Zhu, Thomas Leemhuis, Jose A. Cancelas, Michael Keller, Catherine M. Bollard, Patrick J. Hanley, Zeinab El Boghdadly, Alice Mims, Stella M. Davies, Michael S. Grimley, Adam S. Nelson
Summary: This study retrospectively reviewed 4 patients who received VSTs for the treatment of PML, with one patient who received treatment early successfully clearing JCPyV after treatment, while the other three patients exhibited progressive neurologic decline with a longer delay between diagnosis and treatment.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)